Beijing ACCB Biotech Ltd. (Beijing ACCB Biotech Ltd.)

Established in 2004 and originated from Tsinghua University, it is one of the earliest national high-tech enterprises dedicated to the research and development, production and service of molecular diagnostic reagents related to "personalized cancer treatment", providing early cancer screening, disease diagnosis, and drug selection , Curative effect monitoring, prognosis evaluation, etc. The company's technical team is led by a number of international authoritative experts in the field of oncology, and 80% of the R&D personnel have a master's degree or above. The company has carried out extensive cooperation in the transformation of technological achievements with many top biomedical research institutions and innovation and entrepreneurship institutions at home and abroad, such as Tsinghua University School of Medicine, School of Life Sciences, University of California, San Francisco, and Zhejiang Tsinghua Yangtze River Delta Research Institute.